GI, Surgery & Obstetrics – Full Test
Quiz Summary
0 of 39 Questions completed
Questions:
Information
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
Results
- Review / Skip
- Answered
- Correct
- Incorrect
-
Question 1 of 39
1. Question
Hint
a) 2 marks: acute cellular rejection; infection.
b) 1 mark: liver biopsy.
c) 1 mark: portal lymphocytic infiltrate
d) 2 marks — 1 mark each: blood cultures; CMV PCRCompetency: 1.3.7; 2.4.14.1; 2.4.14.2; 2.4.6.4; 2.2.2
Resource: Demetris AJ et al. Banff schema for grading liver allograft rejection. Hepatology 1997;25:658–663; Levitsky J et al. Acute rejection increases risk of graft failure. Clin Gastroenterol Hepatol 2017 -
Question 2 of 39
2. Question
Hint
RQ = VCO₂/VO₂. Normal ~0.8. Dextrose-only RQ = 1. RQ 1.3: lipogenesis, non-steady-state measurement error.
ASPEN/SCCM Critical Care Nutrition Guidelines 2016; Berger & Pichard, Best Practice & Research Clinical Anaesthesiology 2011
Royal College Competency: 2.4.13.1, 1.3.12.6 -
Question 3 of 39
3. Question
Hint
Bleeding, ACS, anastamotic leak. CT abdomen with enteral contrast. No difference.
WSACS IAH/ACS Guidelines 2013; EAST Trauma Guidelines
Royal College Competency: 2.2.2, 2.4.6.5, 2.4.10.1 -
Question 4 of 39
4. Question
Hint
Correct coagulopathy, warm patient,, correct metabolic disturbances.
If septic shock – hemodynamic support with vasopressors, antibiotics, steroids and additional source control measure as needed
If open abdomen – sedation and analgesia
Return to OR 24-72h for definitive procedure and/or closureEAST Trauma Guidelines; ATLS 10th Edition
Royal College Competency: 2.4.10.1 -
Question 5 of 39
5. Question
Hint
Varices.
UGI endoscopy.
Banding
octreotide, antibiotics (SBP prophylaxis), PPI.
Non-selective beta-blocker (propranolol/nadolol) for re-bleeding prevention. -
Question 6 of 39
6. Question
Hint
Pancreatitis, gallstone*, alcohol, idiopathic, post-ERCP, post-operative, pancreatic cancer, hypertriglyceridemia, hypercalcemia, hereditary, trauma, drug (steroids, azathioprine, thiazide diuretics, valproic acid), congenital biliary/pancreatic duct anomalies. Management is fluids, analgesia, nutrition, no prophylactic antibiotics
Revised Atlanta Classification 2012; ACG Pancreatitis Guidelines 2013
Royal College Competency: 2.4.6.3 -
Question 7 of 39
7. Question
Hint
edema of gallbladder wall, pericholecystic fluid, gall bladder distension
sonographic Murphy’s sign possibleResource: Huffman & Schenker Clin Gastroenterol Hepatol 2010 (acalculous cholecystitis review); WSES Acute Cholecystitis Guidelines 2020
Royal College Competency: 2.4.6.4, 3.4.2 -
Question 8 of 39
8. Question
Hint
IAP measurement via the bladder with installation of 25 mL of sterile saline. Measured in mmHg and measured at end-expiration, supine, transducer leveled at midaxillary line – no abdominal muscle contractions
ACS: sustained IAP > 20 mmHg associated with new organ dysfunction/failureManagement: sedation/pain management, NG drainage, rectal drainage, neuromuscular blockade, volume restriction/diuresis, caution with patient position > 30o head-up (may worsen abdominal compliance), paracentesis for significant ascites
WSACS IAH/ACS Guidelines 2013 (Kirkpatrick et al.)
Royal College Competency: 2.4.6.5, 3.4.1.2 -
Question 9 of 39
9. Question
Hint
RI = peak systolic velocity-end diastolic velocity/peak systolic, indicates degree of congestion
Management includes diuresis/ultrafiltration, nitric oxide, inodilators, reduced PEEP/MAw
Thrombosis prophylaxis = alprostadilKok et al. Radiology 2008; Hepatobiliary Super PDF
Royal College Competency: 2.4.14.3, 1.3.12.4 -
Question 10 of 39
10. Question
Hint
Pharmacologic: metoclopramide or erythromycin. Mechanical: post-pyloric tube.
Ineffective with mechanical obstruction or ischemic bowel. No utility to routine GRV measurement.ASPEN/SCCM 2021 Update; Reignier et al. JAMA 2013
Royal College Competency: 2.4.13.3, 3.1.7, 1.3.9 -
Question 11 of 39
11. Question
Hint
NAC, CRRT, Transplant.
pH 6.5 Cr >300, jaundice pH 6.5. Ammonia.
Yes should be transferred now as meets KCC, which predicts mortality without assessment -
Question 12 of 39
12. Question
Hint
a) Daily caloric requirement: – 25-30 kcal/kg/day × 70 kg = 1750-2100 kcal/day
b) Daily protein requirement: 1.5 g/kg/day = 105 g protein/day
c) Total daily non-protein calories: total 1800 kcal, protein 105g x 4kcal/g = 420 kcal
– Non-protein calories = 1800 – 420 = 1380 kcald) Calories from fat: Typically 30% of 1800 kcal = 540 kcal from fat
e) Calories from carbohydrates:
– Carbohydrate = 1380 – 540 = 840 kcalCompetency: 2.4.13.1, 2.4.13.3, 3.1.7
Resource: McClave SA et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient. JPEN J Parenter Enteral Nutr 2016; 40:159-211 -
Question 13 of 39
13. Question
Hint
Gastric first-line. GRV minimal role, unreliable due to gastric emptying variability. Indications post-pyloric: delayed gastric emptying, gastric outlet obstruction. Prokinetics: erythromycin, metoclopramide. Contraindications: bowel obstruction, mesenteric ischemia.
ASPEN/SCCM Nutrition Guidelines 2016; ASPEN 2021 Update
Royal College Competency: 2.4.13.3, 3.1.7, 1.3.9 -
Question 14 of 39
14. Question
Hint
a) Mechanisms of acetaminophen toxicity:
– Depletion of glutathione stores leading to accumulation of toxic metabolite NAPQI (N-acetyl-p-benzoquinone imine)
– Direct hepatocyte necrosis from NAPQI
– Mitochondrial dysfunction and oxidative stress
– Centrilobular hepatic necrosis (zone 3)b) Situations causing toxicity at lower doses:
– Chronic alcohol use (CYP2E1 induction)
– Malnutrition or fasting (glutathione depletion)
– Concurrent use of CYP2E1 inducers (phenytoin, carbamazepine, rifampin, isoniazid)
– Chronic acetaminophen use (repeated supratherapeutic ingestion)
– Pre-existing liver disease
– HIV infection
– Genetic polymorphisms affecting metabolismc) Mechanism of acute renal failure:
– Direct nephrotoxicity from NAPQI metabolite
– Renal tubular necrosis
– Similar mechanism to hepatotoxicity (glutathione depletion in kidney)
– Acute tubular necrosis from toxic metabolitesd) Cerebral edema timing:
– Stage: Grade 3 or 4 hepatic encephalopathy / Late stage / Advanced liver failure
– Timeframe: 2-4 days post-ingestion / 48-96 hours / Day 3-5e) King’s College Criteria (acetaminophen-induced):
– Arterial pH <7.3 after fluid resuscitation – OR all three of: PT/INR >6.5 (or PT >100 sec), creatinine >300 μmol/L (>3.4 mg/dL), Grade 3-4 encephalopathy
– Arterial lactate >3.5 mmol/L after early fluid resuscitation
– Arterial lactate >3.0 mmol/L after full fluid resuscitationCompetency: 1.3.9, 2.4.4.2, 2.4.6.4, 2.4.12, 2.4.14, 3.1.3.2.3
Resource: O’Grady JG et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439-445 -
Question 15 of 39
15. Question
Hint
a) Prophylactic antibiotics are indicated in necrotic pancreatitis; this patient has no CT evidence of necrosis, therefore there is no clear indication for prophylactic antibiotics, though empiric coverage is reasonable given refractory shock with multi-organ failure of unclear source.
b) Early enteral nutrition is preferred over parenteral nutrition; feeding tube should be placed beyond the ligament of Treitz (post-pyloric).
Competency: 2.4.6.3; 2.4.11.3; 2.4.13.3
Resource: Nathens AB et al. Crit Care Med 2004;32:2524-2536; Marik PE, Zaloga GP. BMJ 2004 -
Question 16 of 39
16. Question
Hint
a) Splanchnic vasoconstrictors (octreotide or vasopressin); endoscopic esophageal variceal band ligation; prophylactic antibiotics. Additional accepted: transjugular intrahepatic portosystemic shunt (TIPS).
Competency: 2.4.6.2; 2.4.11.3
Resource: Garcia-Tsao G et al. Hepatology 2007;46(3):922-938 -
Question 17 of 39
17. Question
Hint
a) Hypophosphatemia; hypokalemia; hypomagnesemia; thiamine deficiency. Additional accepted: cardiac dysrhythmias; delirium; seizures.
Competency: 2.4.13.4; 2.4.9.1
Resource: Mehanna HM et al. BMJ 2008;336(7659):1495-1498 -
Question 18 of 39
18. Question
Hint
a) Mechanical ventilation greater than 48 hours (OR 15.6); coagulopathy (OR 4.3);
History of GI ulceration or bleeding within the past year; traumatic brain or spinal cord injury; burns greater than 35% TBSA. Additional accepted: sepsis; solid organ transplantation; corticosteroid therapy.
Competency: 2.4.6.2; 1.3.3.2
Resource: Cook DJ. Scand J Gastroenterol Suppl 1995;210:48 -
Question 19 of 39
19. Question
Hint
a) Heart failure; severe tricuspid regurgitation; severe pulmonary hypertension (PA pressure >45 mmHg); multiple hepatic cysts; uncontrolled systemic infection or sepsis; unrelieved biliary obstruction. Additional accepted relative contraindications: portal vein thrombosis; hepatocellular carcinoma especially if central; severe coagulopathy; thrombocytopenia less than 20×10⁹/L; moderate pulmonary hypertension.
Competency: 2.4.6.2
Resource: Boyer TD, Haskal ZJ. Hepatology 2010;51(1):306 -
Question 20 of 39
20. Question
Hint
a) 2 marks: gradual resolution over weeks to months (1 mark)
b) 1 mark: Operative re-exploration. Alternate: surgery, call surgery
c) 4 marks: 1 mark each for 2 of: non-concerning explanations: increased portal flow, vessel spasm, cold ischemia time, allograft edema. 1 mark each for 2 of: pathologic: acute cellular rejection, Budd-Chiari, hepatic vein stenosisCompetency: 1.3.11.4; 1.3.2.1; 1.3.2.4; 2.4.14.3; 2.4.7.2
Resource: Pham DT et al. Hepatopulmonary syndrome and liver transplantation. Liver Transpl 2018; Saner FH et al. Coagulation management in liver transplantation. World J Gastroenterol 2017 -
Question 21 of 39
21. Question
Hint
a) 2 marks: drain fluid bilirubin (1 mark); drain bilirubin greater than serum bilirubin (1 mark).
b) 2 marks: monophasic hepatic vein waveform (1 mark); hepatic venous outflow obstruction / congestive hepatopathy (1 mark).
c) 1 mark: anastomotic stenosis / kink.Competency: 1.3.2.4; 2.4.6.4; 2.2.2; 1.2.2; 4
Resource: Sharma S et al. Biliary complications after liver transplantation. World J Gastroenterol 2018; Lee VS et al. Hepatic venous outflow obstruction after liver transplant. Radiology 2020 -
Question 22 of 39
22. Question
Hint
a) 1 mark: posterior reversible encephalopathy syndrome (PRES).
b) 2 marks: MRI brain; posterior white matter vasogenic edema.
c) 2 marks — 1 mark each: reduce/hold tacrolimus; treat hypertension.Competency: 1.3.2.3; 2.4.4.2; 2.4.14.3; 1.3.9.2; 2.2.2
Resource: Bartynski WS. Posterior reversible encephalopathy syndrome. AJNR 2008;29:1036–1042; Hinchey J et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500 -
Question 23 of 39
23. Question
Hint
Dextrose 3.4 cal/g × 170 g/L = 578 cal/L. Protein 4 cal/g × 70 g/L = 280 cal/L. SMOF = soya, medium-chain triglycerides, olive oil, fish oil. Higher omega-3 than intralipid.
ASPEN/SCCM Nutrition Guidelines 2016
Royal College Competency: 2.4.13.3, 3.1.7 -
Question 24 of 39
24. Question
Hint
a) 2 marks: predicts mortality without transplant (1 mark); 3-month survival (1 mark).
b) 1 mark: any one of: hepatocellular carcinoma (Milan criteria); hepatopulmonary syndrome; portopulmonary hypertension; familial amyloid polyneuropathy; primary hyperoxaluria; cystic fibrosis; hilar cholangiocarcinoma (1 mark).
c) 2 marks — 1 mark each: creatinine confounded by pre-existing CKD / underestimates hepatic severity; does not account for acute or acute-on-chronic liver failure trajectory.
d) 1 mark: predicts 3-month mortality post-TIPS / used to assess TIPS candidacy.Competency: 1.3.2.4; 2.4.6.4; 2.2.1
Resource: Kamath PS et al. Model for end-stage liver disease. Hepatology 2001;33:464–470 -
Question 25 of 39
25. Question
Hint
a) 1 mark: ischemia-reperfusion injury from DCD/long warm ischemic time causes expected transaminase elevation.
b) 2 marks: peak day 1–3 then trend down (1 mark); failure to downtrend / rising bilirubin / coagulopathy worsening / haemodynamic instability (1 mark).
c) 1 mark: hepatopulmonary syndrome resolves slowly over weeks to months after transplant.
d) 1 mark: gradual improvement over weeks to months.
e) 2 marks — 1 mark each: worsening rather than stable or improving trajectory; new bilateral infiltrates / consolidation on imaging; haemodynamic deterioration. Alternate: fever with new infiltrates suggesting infection.Competency: 1.3.2.4; 2.4.6.4; 2.4.14.3; 2.2.1
Resource: Porrett PM et al. Complications after transplantation. Surg Clin North Am 2010;90:679–710 -
Question 26 of 39
26. Question
Hint
a) 1 mark: ICP monitoring — elevated edema, normal HE (1 mark).
b) 2 marks — 1 mark each for any 2 met: pH <7.30 (lactate 5.8 suggests acidosis); creatinine >301 µmol/L; Grade III/IV encephalopathy; PT >100s.
c) 1 mark: durable / refractory elevated intracranial pressure.
d) 2 marks: intraoperative RRT used to control ammonia (1 mark); target: ammonia reduction / control of hyperammonaemia to reduce cerebral edema risk during reperfusion (1 mark).Competency: 1.3.2.4; 1.3.12.3; 2.4.4.1; 2.4.5.1; 2.4.6.4; 3.1.9
Resource: O’Grady JG et al. King’s College Hospital criteria for orthotopic liver transplantation. Gastroenterology 1989;97:439–445 -
Question 27 of 39
27. Question
Hint
Permissive underfeeding BMI >30: 60–70% target calories (11–14 kcal/kg actual or 22–25 kcal/kg IBW). Protein 2–2.5 g/kg IBW/day. Higher protein if BMI >40.
ASPEN/SCCM Nutrition Guidelines 2016 (Obese Critically Ill)
Royal College Competency: 2.4.13.1 -
Question 28 of 39
28. Question
Hint
Refeeding syndrome.
Hypophosphatemia.
Cardiomyopathy, encephalopathy, proximal myopathy, hemolytic anemia, WBC phagocytosis impairment, thrombocytopenia
Labs: phosphate, magnesium, potassium.ASPEN/SCCM Nutrition Guidelines 2016; Mehanna et al. BMJ 2008
Royal College Competency: 2.4.9.1, 2.4.13.1 -
Question 29 of 39
29. Question
Hint
C. diff antigen/PCR, flexible sigmoidoscopy (pseudomembranes, CMV biopsy), AXR/CT (toxic megacolon). Bladder pressure. Decompressive laparotomy/colectomy for toxic megacolon.
ACG Guidelines on C. difficile 2021; WSACS Abdominal Compartment Syndrome Guidelines 2013
Royal College Competency: 2.4.6.1, 2.4.6.5, 3.4.1.2 -
Question 30 of 39
30. Question
Hint
Mortality – 3-month waitlist.
Creatinine, Bilirubin, INR, Serum Sodium (sodium added in 2016 – hyponatremia correlates with survival). Hepatocellular carcinoma, hepatopulmonary syndrome, portopulmonary hypertension, cystic fibrosis, hilar cholangiocarcinoma, hyperoxaluriaOPTN/UNOS MELD Policy; Kim et al. Hepatology 2008
Royal College Competency: 2.4.14 -
Question 31 of 39
31. Question
Hint
Neostigmine (2 mg IV)
Acetylcholinesterase inhibitor – blocking metabolism of Ach at cholinergic synapses – used in Ogilvie’s to increase peristalsis (muscarinic parasympathetic effect)
bradycardiaPonec et al. NEJM 1999; ACG Guidelines on Colonic Pseudo-obstruction
Royal College Competency: 2.4.6.1, 1.3.9 -
Question 32 of 39
32. Question
Hint
CT: pneumatosis, pneumoperitoneum, bowel wall thickening, diminished enhancement, bowel dilatation, vascular defects, portal air.
Portal venous gas: peripheral liver (left lobe), mesenteric ischemia, high mortality, emergent surgery. Pneumobilia: central, post-biliary instrumentation.
Management: IV fluid, broad spectrum antibiotics, no enteral feeds/meds, anticoagulation if thromboembolic origin, intra-arterial catheter directed vasodilator infusions or thrombolyticsBrandt & Boley NEJM 2000; Menke et al. systematic review 2010
Royal College Competency: 2.4.6.1, 2.2.2 -
Question 33 of 39
33. Question
Hint
Obstetrical conditions → ARDS: AFE, trophoblastic embolism, pre-eclampsia, obstetrical sepsis, placental abruption. Physiologic changes: FRC decreased, PaCO₂ decreased, static compliance unchanged, chest wall resistance lower, MV increased, VO₂ increased.
Resource: SCCM Critical Care in Obstetrics; Lapinsky et al. Crit Care Med 2019
Royal College Competency: 1.3.2.9, 2.4.17 -
Question 34 of 39
34. Question
Hint
Answers: PRES, CVST. MRV, LMWH best, heparin/warfarin/DOAC avoid.
Resource: Silvis et al. Lancet Neurol 2017 (CVST); ESC Pregnancy and Cardiovascular Disease 2018
Royal College Competency: 2.4.4.2, 2.4.17 -
Question 35 of 39
35. Question
Hint
AFLP, FFP, IV dextrose. Delivery. DIC, Pancreatitis, pleural effusions/ascites, infection, renal failure.
Resource: Knight et al. BJOG 2008 (AFLP); CMACE UK AFLP Guidelines
Royal College Competency: 2.4.6.4, 2.4.17.2 -
Question 36 of 39
36. Question
Hint
a) Differential diagnosis:
– HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets)
– Severe preeclampsia
– Acute fatty liver of pregnancy (AFLP)
– Disseminated intravascular coagulation (DIC)
– Thrombotic thrombocytopenic purpura (TTP)
– Hemolytic uremic syndrome (HUS)
– Sepsis with liver dysfunction
– Postpartum hemorrhage with coagulopathyb) Top two diagnoses:
– HELLP syndrome
– DIC (possibly secondary to HELLP or other cause)c) Additional bloodwork and expected findings:
– Peripheral blood smear: schistocytes, fragmented RBCs (microangiopathic hemolysis)
– Haptoglobin: low/undetectable (hemolysis)
– Indirect bilirubin: elevated (hemolysis)
– Fibrinogen: low <2 g/L (DIC)
– D-dimer: elevated (DIC, fibrinolysis)
– ADAMTS13 activity: low if TTP (<10%)
– Lactate: may be elevated if AFLPd) Explanation for INR 2.2 and oozing:
– Disseminated intravascular coagulation (DIC)
– Consumption of clotting factors
– Coagulopathy of critical illness
– Liver dysfunction impairing synthesis of clotting factors
– Platelet dysfunction and thrombocytopenia
– Consumptive coagulopathye) Treatment priorities:
– Urgent delivery if still pregnant (already delivered in this case)
– Blood pressure control (labetalol, hydralazine, nifedipine) – target <160/110
– Magnesium sulfate for seizure prophylaxis (4-6 g loading dose, 1-2 g/hr infusion)
– Platelet transfusion if <20-50 × 10⁹/L and bleeding or pre-procedure
– Fresh frozen plasma and cryoprecipitate for coagulopathy if active bleeding
– Supportive care in ICU with close monitoring
– Treat DIC if present
– Avoid aspirin and NSAIDsCompetency: 2.4.6.4, 2.4.17.2
Resource: — Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004; 103:981-991 -
Question 37 of 39
37. Question
Hint
a) Peripartum cardiomyopathy; community-acquired pneumonia; pulmonary embolism; asthma exacerbation; ARDS.
b) Peripartum cardiomyopathy.
c) Reduce afterload and preload (nitrates, hydralazine, furosemide); initiate inodilator therapy (milrinone or dobutamine); fetal heart rate monitoring with consideration of urgent caesarean section for fetal distress or non-resolving maternal heart failure.
d) ACE inhibitors; aldosterone antagonists.
e) Mechanical circulatory support: veno-arterial ECMO or ventricular assist device.
f) Advanced maternal age (>30 years); multiparity. Additional accepted: multiple gestation; preeclampsia or gestational hypertension; African descent.
Competency: 2.4.17.2; 2.4.17.3; 2.4.3.1; 2.4.3.2
Resource: Sliwa K et al. Eur J Heart Fail 2010;12(8):767-778 -
Question 38 of 39
38. Question
Hint
a) 2 marks: two from: hypertensive encephalopathy / PRES; intracranial hemorrhage; cerebral venous sinus thrombosis; new-onset epilepsy; CNS infection; TTP (1 mark each).
b) 3 marks: NMDA receptor antagonism / cerebral vasodilation reducing cortical excitability (1 mark); toxic level >3.5–5 mmol/L — first sign: loss of deep tendon reflexes (1 mark); calcium gluconate IV (1 mark).
c) 2 marks — any 2: increased volume of distribution; increased GFR / accelerated renal clearance; reduced albumin / altered protein binding.Competency: 1.3.2.9; 1.3.3.2; 2.4.4.1; 2.4.17.2; 2.4.17.3
Resource: Magee LA et al. Cochrane Database Syst Rev 2010; SOGC. J Obstet Gynaecol Can 2022;44:547–571 -
Question 39 of 39
39. Question
Hint
a) 3 marks — 1 mark each: reduced FRC from diaphragmatic displacement; increased oxygen consumption; airway edema and mucosal hypervascularity. Alternate: reduced lower oesophageal sphincter tone / aspiration risk; aortocaval compression reducing cardiac output supine.
b) 2 marks: fetal lung maturity (1 mark) — betamethasone 12 mg IM q24h × 2 doses; maternal respiratory failure / ARDS (1 mark) — dexamethasone 6 mg IV q6h × 4 doses;
c) 2 marks: maternal oxygenation trajectory; gestational age and fetal viability (1 mark); non-reassuring fetal heart rate tracing / prolonged fetal bradycardia (1 mark).Competency: 1.3.2.9; 2.4.2.1; 2.4.17.1; 2.4.17.3
Resource: Lapinsky SE. Clin Chest Med 2011;32:13–26; SMFM. Am J Obstet Gynecol 2021;224:B13–B15